• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Philippe Métellus, Béma Coulibaly, +13 authors Dominique Figarella‐Branger
  • Medicine, Biology
  • Acta Neuropathologica
  • 2010 (First Publication: 16 November 2010)
  • The phenotypic heterogeneity of low-grade gliomas (LGGs) is still inconsistently explained by known molecular abnormalities in patients treated according to the present standards of care. IDH1 codonExpand
  • Philippe Métellus, Béma Coulibaly, +9 authors Dominique Figarella-Branger
  • Medicine
  • Cancer
  • 2009 (First Publication: 15 October 2009)
  • BACKGROUND O(6)-methylguanine-DNA methyltransferase (MGMT) is a key enzyme in the DNA repair process after alkylating agent action. Epigenetic silencing of the MGMT gene by promoter methylation hasExpand
  • P. Menei, P. Métellus, +5 authors The Neuro-oncology Club of the French Society of Neurosurgery
  • Medicine
  • Annals of Surgical Oncology
  • 2010 (First Publication: 5 May 2010)
  • BackgroundCarmustine-releasing wafers (Gliadel®) have been available and reimbursed in France since 2005.MethodsA retrospective multicenter study was conducted in 26 French Departments ofExpand
  • Philippe Métellus, Marylin Barrie, +5 authors Jacques Guyotat
  • Medicine
  • Brain : a journal of neurology
  • 2007 (First Publication: 2 April 2007)
  • Ependymomas account for 2% of all intracranial tumours in adults. Considerable controversy continues to exist with regard to their prognostic factors and therapeutic management due to the rarity andExpand
  • Olivier L Chinot, Maryline Barrié, +9 authors Dominique Figarella‐Branger
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2007 (First Publication: 20 April 2007)
  • PURPOSE This phase II study evaluated the efficacy and safety of a 7-day on/7-day off regimen of temozolomide before radiotherapy (RT) in patients with inoperable newly diagnosed glioblastoma. Expand